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ABSTRACT

The present invention relates to therapeutic uses of

cyclosporin A to reduce adverse effects of neural injury.
10 Claims, 4 Drawing Sheets
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PROTECTION AGAINST TRAUMATIC

injuries, the composition comprising an amount of
cyclosporin A effective for reducing adverse effects of
traumatic brain injury and pharmaceutically acceptable car

BRAIN INJURY
FIELD OF THE INVENTION

rier.

Additional objects and advantages of the present inven

The present invention relates to a method for reducing
adverse effects of a neural injury by administering to a

tion Will become readily apparent to those skilled in this art

from the folloWing detailed description, Wherein embodi

patient a therapeutically effective amount of cyclosporin A.

ments of the invention are described simply by Way of

BACKGROUND OF THE INVENTION

Severe traumatic brain injuries (TBI) initiate a cascade of
events that lead to a plethora of adverse effects including
dramatic elevations of intracranial pressure (ICP) and dys
function of cerebrovascular regulatory mechanisms essential
for survival. Ischemic brain injury is observed universally in
those patients Who die folloWing severe TBI. Intracranial

10

illustrating of the best mode contemplated in carrying out
the invention. As Will be realiZed, the invention is capable of
other and different embodiments, and its several details are

capable of modi?cations in various obvious respects, all
Without departing from the invention. Accordingly, the
draWings and description are to be regarded as illustrative in
15 nature and not as restrictive.

hypertension (IH) folloWing traumatic brain injury is asso
BRIEF DESCRIPTION OF DRAWINGS

ciated With direct effects on cerebral perfusion Which may be

responsible for secondary ischemia. The contributions of
both post-traumatic cerebral edema and alteration in cerebral
blood volume to ICP appear to vary based on the length of

time after the primary mechanical insult. This combination
of vasomotor dysfunction and abnormalities in vascular
permeability is characteristic of acute in?ammation.
The mortality rate from severe traumatic brain injury
(TBI) in the United States alone amounts to 9—30 deaths per

FIG. 1 illustrates the effect of CsA administration before
TBI on cortical lesion volume.
20

25

TBI on cortical lesion volume.

100,000. Those suffering brain injury requiring medical
treatment number 160—300 per 100,000, With approximately
20 percent of patients admitted to treatment facilities sustain

DESCRIPTION OF THE INVENTION

The present invention provides a method of treating a

a moderate to severe degree of injury as measured by the

GlasgoW Coma Score (GCS) of 3—12. Direct costs of brain
injury, including the costs of treatment and long-term care,

30

as Well as indirect costs, including disablement and the loss

of productivity of brain injury patients and other such costs,
are staggering.

One approach to treating severe traumatic brain injuries is
With hypothermia, as in US. Pat. No. 5,486,204 to Clifton.
The procedure includes the introduction of speci?ed medi

35

formulating this compound into pharmaceutical composi
40

ing patients.
There eXists a need to provide simpli?ed methodology for

45

problems attendant upon multistep, complicated processes
50

pills, ampoules or suppositories comprising a compound of
the invention.

55

“Pharmaceutical composition” means physically discrete
coherent portions suitable for medical administration. “Phar
maceutical composition in dosage unit form” means physi
cally discrete coherent units suitable for medical
administration, each containing a daily dose or a multiple
(up to four times) or a sub-multiple (doWn to a fortieth) of
a daily dose of the active compound of the invention in

60

lope. Whether the composition contains a daily dose, or for

skill in the art upon examination of the folloWing or may be

learned from the practice of the invention. The objects and
advantages of the invention may be realiZed and obtained as

particularly pointed out in the appended claims.
According to the present invention, the foregoing and

eXcipient acceptable for delivery of the compounds to the

tablets (including loZenges and granules), dragees, capsules,

for treating severe traumatic brain injuries.
An object of the present invention is a method of treating
a mammal suffering from traumatic brain injury.
Additional objects, advantages and other features of the
invention Will be set forth in the description Which folloWs
and in part Will become apparent to those having ordinary

tions.
The compounds for use in the present invention can be
administered as a pharmaceutical composition. The pharma
ceutical compositions used in the methods of this invention
for administration to animals and humans comprise an active
agent in combination With a pharmaceutical carrier or
brain.
The pharmaceutical compositions can be in the form of

humans. The present invention addresses and solves the

DISCLOSURE OF THE INVENTION

tically effective amount of cyclosporin A.
CyclosporinAis knoWn and has been proposed for use for
various therapeutic methods. For example, US. Pat. Nos.
4,117,118 and 5,766,629, Which are incorporated herein in

methods for preparing this compound, and methods for

introduction of medications, and rigidly controlled reWarm
ing to reduce the incidence of reWarming shock in recover

treating traumatic brain injuries in mammals, including

mammal, including humans, suffering from traumatic brain
injury, Which method comprises administering a therapeu

their entirety by reference thereto, describe this compound,

cation to reduce the risk of cardiac arrhythmia and a com

plicated protocol for the treatment Which de?nes time,
temperature, rate of change of temperature, the timing of the

FIG. 2 illustrates the effect of CsA administration pre- and
post-injury on cortical lesion volume.
FIG. 3 illustrates the effect of CsA administration pre- and
post-injury on cortical lesion volume.
FIG. 4 illustrates the effect of CsA administration after

association With a carrier and/or enclosed Within an enve

eXample, a half, a third or a quarter of a daily dose Will

other objects are achieved in part by a method of treating a

depend on Whether the pharmaceutical composition is to be

mammal, including humans, suffering from traumatic brain
injury, Which method comprises administering a therapeu

times a day, respectively.

tically effective amount of cyclosporin A.
Another aspect of the present invention is a pharmaceu
tical composition for treatment of severe traumatic brain

administered once or, for eXample, tWice, three times or four
65

Advantageously, the compositions are formulated as dos

age units, each unit being adapted to supply a ?Xed dose of

active ingredients. Tablets, coated tablets, capsules,

US 6,255,280 B1
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ampoules and suppositories are examples of preferred dos

?avoring additions (e.g., peppermint oil and eucalyptus oil,
and sWeetening agents, (e.g., saccharin and aspartame).
The pharmaceutical compositions Will generally contain

age forms according to the invention. It is only necessary
that the active ingredient constitute an effective amount, i.e.,
such that a suitable effective dosage Will be consistent With

from about 0.0001 to 90 Wt. %, preferably about 0.01 to 10

the dosage form employed in single or multiple unit doses.

Wt. % of the active ingredient by Weight of the total
composition. In addition to the active agent, the pharma

The exact individual dosages, as Well as daily dosages, are

determined according to standard medical principles under

ceutical compositions and medicaments can also contain

the direction of a physician or veterinarian.
The active agents can also be administered as

other pharmaceutically active compounds.
Any diluent in the pharmaceutical compositions of the

suspensions, solutions and emulsions of the active com
pound in aqueous or non-aqueous diluents, syrups, granu
lates or poWders. Diluents that can be used in pharmaceu

10

relation to the pharmaceutical compositions. Such compo
sitions may include solvents of molecular Weight less than

tical compositions (e.g., granulates) containing the active
compound adapted to be formed into tablets, dragees, cap
sules and pills include the folloWing: (a) ?llers and
extenders, e.g., starch, sugars, mannitol and silicic acid; (b)
binding agents, e.g., carboxymethyl cellulose and other
cellulose derivatives, alginates, gelatine and polyvinyl pyr

200 as the sole diluent.
15

locally, preferably orally or parenterally, especially
20

mg/kg, preferably from about 20 mg/kg to about 40 mg/kg,

25

Will be a function of the nature and body Weight of the
human or animal subject to be treated, the individual reac
tion of this subject to the treatment, type of formulation in
Which the active ingredient is administered, the mode in
Which the administration is carried out and the point in the

30

progress of the disease or interval at Which it is to be
administered. Thus, it may in some case suffice to use less
than a minimum dosage rate, While other cases an upper
limit must be exceeded to achieve the desired results. Where
larger amounts are administered, it may be advisable to
divide these into several individual administrations over the

The tablets, dragees, capsules and pills comprising the
active agent can have the customary coatings, envelopes and
protective matrices, Which may contain opaci?ers. They can
be so constituted that they release the active ingredient only
or preferably in a particular part of the intestinal tract,
possibly over a period of time. The coatings, envelopes and

protective matrices may be made, for example, from poly

course of the day.

meric substances or Waxes.

The active ingredient can also be made up in microen
capsulated form together, With one or several of the above
mentioned diluents.

The diluents to be used in pharmaceutical compositions
adapted to be formed into suppositories can, for example, be
the usual Water-soluble diluents, such as polyethylene gly
cols and fats (e.g., cocoa oil and high esters, (e.g., C14
alcohol With C16-fatty acid]) or mixtures of these diluents.
The pharmaceutical compositions Which are solutions and
emulsions can, for example, contain the customary diluents
(With, of course, the above-mentioned exclusion of solvents

35

40

45

folloWing traumatic brain injury such as by Way of a single
50

dosage is administered less than about 6 hours after TBI,

55

For parenteral administration, solutions and suspensions

Cyclosporin A may also be administered in association

With other therapeutic agents including, for example, anti

The pharmaceutical compositions Which are suspensions

biotics or antiviral agents.
60

Water, ethyl alcohol, propylene glycol, surface active agents
(e.g., ethoxylated isostearyl alcohols, polyoxyethylene sor
bitols and sorbitan esters), polycrystalline cellulose, alumi

The folloWing non-limiting examples are given by Way of
illustration only.
EXAMPLE 1

num methahydroxide, agar—agar and tragacanth, or mix

The pharmaceutical compositions can also contain bulk
ing agents and preservatives, as Well as perfumes and

HoWever, one or more doses may be administered after 6
hours such as from about 6 hours to about 24—48 hours after

injury.

ampoules and, if appropriate, blood-isotonic.

tures thereof.

or multiple doses or from sustained release compositions
over a period of time, such as immediately after the T131 to
about 1 or more day after the TBI. Preferably, the initial
such as from about 15 minutes to about 1 hour after injury.

should be sterile, e.g., Water or arachis oil contained in

can contain the usual diluents, such as liquid diluents, e.g.,

Will be determined by the physician taking into account the
age, Weight and general health of the subject. In other
embodiments of the present invention, the cyclosporin A
may be administered directly to the brain, e.g.
intraventricularly, intracerebrally or intracisternally. The
dosage may be administered in one or more treatments

alcohol, polyethylene glycols and fatty acid esters of sorbitol
or mixtures thereof.

the most rapid delivery of the active agent to the brain. A
suitable dosage for obtaining attenuation of the effects of
traumatic brain injury is from about 1 to about 1000 mg/kg
body Weight, such as from about 10 to about 100 mg/kg

body Weight, although the optimum dosage of cyclosporin A

having a molecular Weight beloW 200, in the presence of a

are Water, ethyl alcohol, isopropyl alcohol, ethyl carbonate,

It is presently preferred to administer cyclosporin A
parenterally, such as intravenously, in a bolus, so as to obtain

surface-active agent), such as diluents, dissolving agents and
emulsi?ers. Speci?c non-limiting examples of such diluents

ethyl acetate, benZyl alcohol, benZyl benZoate, propylene
glycol, 1,3-butylene glycol, dimethylformamide, oils (for
example, ground nut oil, glycerol, tetrahydrofurfuryl

perlingually, or intravenously.
The dosage rate, e.g., about 0.0001 to about 200 mg/kg of
body Weight, such as from about 10 mg/kg to about 150

sodium bicarbonate; (e) agents for retarding dissolution,
e.g., paraf?n;
resorption accelerators, e.g., quaternary
ammonium compounds; (g) surface active agents, e.g., cetyl
alcohol, glycerol monostearate; (h) adsorptive carriers, e.g.,
kaolin and bentonite;
lubricants, e.g., talc, calcium and
magnesium stearate and solid polyethylene glycols.

The active compound is administered perorally, parenter

ally (for example, intramuscularly, intraperitoneally,
subcutaneously, transdermally or intravenously), rectally or

rolidone; (c) moisturiZing agents, e.g., glycerol; (d) disinte
grating agents, e.g., agar—agar, calcium carbonate and

present invention may be any of those mentioned above in

Pretreatment With Cyclosporin A (CsA) in C57B16 Mice
65

Adult C57B16 mice Were pretreated With a single sys
temic injection of one of three different doses of CsA (high

(150 mg/kg) medium (40 mg/kg) loW (20 mg/kg)) 5 min

US 6,255,280 B1
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prior to a moderate cortical contusion. Animals also received

medium (40 mg/kg), or loW (20 mg/kg) With CsA systemi

an additional single systemic injection 24 hr after injury
(n=8/group). Control animals received vehicle alone. Ani
mals Were killed 7 days post-injury and the brains assessed

cally. 7 days folloWing TBI mice Were killed and stereo
logical methods used to determine lesion volume siZe.
Values are group means (n=8/group):SE *p<0.01 vs

for changes in lesion volume siZe utilizing image analysis
and stereology. The lesion volume Was signi?cantly reduced
in all animals injected With CsA as compared to vehicle
controls. An AN OVA demonstrated a signi?cant dose effect
such that the greatest protection Was afforded by animals
receiving the loWest dose. The animals treated With 20
mg/kg CsA demonstrated a 45% reduction in lesion volume.

vehicle *p<0.01 vs medium and high.
FIG. 2.

Cortical lesion volume Was signi?cantly reduced in ICR
10

TBI mice Were killed and stereological methods used to

EXAMPLE 2
Pre- vs Post-treatment With Cyclosporin A in ICR Mice

determine lesion volume siZe. Values are group means

Adult ICR mice Were either pre-treated systemically With

medium (40 mg/kg) or loW (20 mg/kg) doses of CsA 5 min
prior to TBI or With a loW dose (20 mg/kg) 15 min after TBI.
These animals subsequently received an additional injection
24 h later. Control animals received vehicle 5 min prior and
24 h after TBI. Seven days after injury the animals Were

mice treated either pre- (medium 40 mg/kg; loW 20 mg/kg)
or post (20 mg/kg) With CsA systemically. 7 days folloWing

15

(n=8/group):SE *p<0.01 vs vehicle *p<0.01 vs pre
medium.
FIG. 3.

Cortical lesion volume Was signi?cantly reduced in SD
rats treated either pre- (medium 40 mg/kg/ loW 20 mg/kg) or
20

post (20 mg/kg) With CsA systemically. 7 days folloWing

killed and the brains assessed for possible changes in lesion
volume siZe. All animals receiving CsA shoWed signi?cant

determine lesion volume siZe. Values are group means

amelioration of lesion volume and animals treated after the
injury Were equivalent to pre-treated loW dose animals. In

(n=10/group):SE *p<0.01 vs vehicle *p<0.01 vs pre
medium.

TBI rats Were killed and stereological methods used to

addition, the effect Was observed in an additional strain of 25
mice. The results are shoWn in FIG. 2.

EXAMPLE 3
Pre- vs Post-treatment With CsA in Rats
Adult SD rats Were either pre-treated systemically With

Early initiation of therapy resulted in a signi?cant reduc
tion in cortical lesion volume. This same level of protection
of cortical tissue Was also observed With the 1 h delay. If
30

medium (40 mg/kg) or loW (20 mg/kg) doses of CsA 5 min

treatment Was delayed for 6 h there Was little or no sparing.

hoWever, a delay of 24 h again shoWed some protection.

prior to TBI or With a loW dose (20 mg/kg) 15 min after TBI.

Bars=group meanszSEM (n=3/group).

These animals subsequently received an additional injection
24 h later. Control animals received vehicle 5 min prior and
24 h after TBI. Seven days after injury the animals Were
killed and the brains assessed for possible changes in lesion
volume siZe. Identical to that found in the mice, all animals
treated With CsA shoWed signi?cant reductions in the lesion
volume siZe. Post-injury administration of CsA resulted in

FIG. 4.

35

In the previous descriptions, numerous speci?c details are
set forth, such as speci?c materials, structures, chemicals,
processes, etc., in order to provide a better understanding of
the present invention. HoWever, the present invention can be

40

practiced Without resorting to the details speci?cally set
forth. In other instances, Well-knoWn processing structures

signi?cant reductions (40%) in lesion volume. The results

have not been described in detail in order not to unneces

are shoWn in FIG. 3.

sarily obscure the present invention.
Only the preferred embodiment of the invention and but

EXAMPLE 4

Time Course of Initiation of CsA Treatment FolloWing TBI
We administered CsA at a concentration of 20 mg/kg to

animals (n=3 adult rats/group) folloWing a moderate level of
TBI. The CsA therapy (single systemic injection) Was ini
tiated at different time intervals folloWing the injury (15 m,
1 h, 6 h, 24 h). Animals Were administered a second injection
24 h after the ?rst injection. All animals survived for 7 days
folloWing injury. Brains Were assessed for changes in lesion

50

volume siZe utiliZing image analysis and stereological tech

niques.
The results, as shoWn in FIG. 4, indicate that the WindoW
for therapeutic intervention in this model is at least 1 h and

55

60

immediately folloWing the injury and then closes rapidly
(3—6 h post TBI) and reopens around by 24 h.

C57B16 mice treated prior to injury With high (150 mg/kg),

tissue damage by reducing lesion volume siZe by more
than about 5%.

2. The method of claim 1, comprising:

administering the cyclosporin A orally.

DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1.
Cortical lesion volume Was signi?cantly reduced in

the cerebral corteX, Which method comprises:
administering a therapeutically effective amount of
cyclosporin A in a dose from about 1 to about 1000
mg/kg to a mammal in need thereof Within about 48
hours after the injury to reduce or ameliorate brain

may even be as long as 24 h. The lack of protection at 6 h

may relate directly to changes in the blood-brain barrier
because in this rodent model of TBI, the BBB is opened

a feW eXamples of its versatility are shoWn and described in
the present disclosure. It is to be understood that the present
invention is capable of use in various other combinations
and environments and is capable of changes or modi?cations
Within the scope of the inventive concept as expressed
herein.
What is claimed is:
1. A method for treating a mammal suffering from trau
matic brain injury caused by an external mechanical force on

65

3. The method of claim 1, comprising:
reducing lesion volume siZe by about 10% to about 45%.
4. The method of claim 1, Wherein the traumatic injury
results from a non-penetrating head Wound.

US 6,255,280 B1
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5. The method of claim 1, comprising:

administering the cyclosporin A in a dose from about 10

administering the cyclosporin A parenterally.
6. The method of claim 1, comprising:

mg/kg to about 150 mg/kg.
9. The method of claim 1, comprising:

administering the cyclosporin A to a human in at least one

administering the cyclosporin A in a dose from about 20

dose Within about 24 hours after injury.
7. The method of claim 1, comprising:
administering the cyclosporin Ato a human in at least tWo
doses Within about 24 hours after injury.
8. The method of claim 1, comprising:

mg/kg to about 40 mg/kg.
10. The method of claim 1, comprising:
administering the cyclosporin A to a human.
*
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